The prevalence of osteoarthritis and its association with geriatric syndromes in people over 65: data from the Russian epidemiological study EVKALIPT

Cover Page

Cite item

Full Text

Abstract

Background. Osteoarthritis (OA) in elderly and senile patients is not only common, but also one of the main diseases affecting the duration of active life, its quality, the appearance of addictions and loss of autonomy. Data on the relationship between OA and geriatric syndromes (GS) in our country are extremely scarce.

Aim. To estimate the prevalence of OA and to analyze its associations with HS in persons aged ≥65 years.

Materials and methods. The study included 4308 people (30% of men) aged 65 to 107 years, living in 11 regions of Russia. The patients were divided into 2 groups: with OA (n=2464) and without OA (n=1821). All patients underwent a comprehensive geriatric assessment.

Results. The prevalence of OA was 57.6%. With age, the frequency of OA increased significantly. According to the results of a comprehensive geriatric assessment, patients with OA had lower walking speed, the sum of points on the Bartel, Lawton scales and a short battery of physical functioning tests and higher – the sum of points on the geriatric scale of depression and the age is not a hindrance scale. Patients with OA rated the quality of life and health status lower and higher – the intensity of pain syndrome. Patients with OA were more likely to use any assistive device, with the exception of a wheelchair. In patients with OA, the most common HS were chronic pain syndrome (92%), senile asthenia syndrome (64%), basic (66%) and instrumental (56%) dependence in everyday life, cognitive impairment (62%), probable depression (51%) and urinary incontinence (50%). Univariate regression analysis showed that OA is associated with a 1.2–3.0-fold increase in the risk of a number of GS and a 28% decrease in the risk of malnutrition.

Conclusion. OA is widespread in the elderly population. The presence of OA is associated with a number of GS associated with loss of autonomy.

About the authors

Anton V. Naumov

Pirogov Russian National Research Medical University

Author for correspondence.
Email: nanton78@gmail.com
ORCID iD: 0000-0002-6253-621X

д-р мед. наук, проф. каф. болезней старения ФДПО, зав. лаб. заболеваний костно-мышечной системы ОСП РГНКЦ

Russian Federation, Moscow

Natalya M. Vorobyeva

Pirogov Russian National Research Medical University

Email: nanton78@gmail.com
ORCID iD: 0000-0002-6021-7864

д-р мед. наук, зав. лаб. сердечно-сосудистого старения ОСП РГНКЦ

Russian Federation, Moscow

Natalia O. Khovasova

Pirogov Russian National Research Medical University

Email: nanton78@gmail.com
ORCID iD: 0000-0002-3066-4866

канд. мед. наук, доц. каф. болезней старения ФДПО, ст. науч. сотр. лаб. заболеваний костно-мышечной системы ОСП РГНКЦ

Russian Federation, Moscow

Viktoriia I. Moroz

Pirogov Russian National Research Medical University

Email: nanton78@gmail.com
ORCID iD: 0000-0001-6040-1090

ассистент каф. болезней старения ФДПО, мл. науч. сотр. лаб. заболеваний костно-мышечной системы ОСП РГНКЦ

Russian Federation, Moscow

Alexey D. Meshkov

Pirogov Russian National Research Medical University

Email: nanton78@gmail.com
ORCID iD: 0000-0002-5187-0108

канд. мед. наук, врач-ревматолог, ст. науч. сотр. лаб. заболеваний костно-мышечной системы ОСП РГНКЦ

Russian Federation, Moscow

Tatiana M. Manevich

Pirogov Russian National Research Medical University

Email: nanton78@gmail.com
ORCID iD: 0000-0002-2196-1068

канд. мед. наук, зав. отд-нием неврологии ОСП РГНКЦ

Russian Federation, Moscow

Olga N. Tkacheva

Pirogov Russian National Research Medical University

Email: nanton78@gmail.com
ORCID iD: 0000-0002-4193-688X

д-р мед. наук, проф., зав. каф. болезней старения ФДПО, дир. ОСП РГНКЦ, гл. внештат. гериатр Минздрава России

Russian Federation, Moscow

Yulia V. Kotovskaya

Pirogov Russian National Research Medical University

Email: nanton78@gmail.com
ORCID iD: 0000-0002-1628-5093

д-р мед. наук, проф., зам. дир. по научной работе ОСП РГНКЦ

Russian Federation, Moscow

Elena V. Selezneva

National Research University “Higher School of Economics”

Email: nanton78@gmail.com
ORCID iD: 0000-0001-6623-6815

канд. экон. наук, ст. науч. сотр.

Russian Federation, Moscow

Lilia N. Ovcharova

National Research University “Higher School of Economics”

Email: nanton78@gmail.com
ORCID iD: 0000-0002-7266-707X

д-р экон. наук, проректор

Russian Federation, Moscow

References

  1. Sacitharan PK. Ageing and Osteoarthritis. Subcell Biochem. 2019;91:123-59. doi: 10.1007/978-981-13-3681-2_6
  2. Mandl LA. Osteoarthritis year in review 2018: clinical. Osteoarthritis Cartilage. 2019;27(3):359-64. doi: 10.1016/j.joca.2018.11.001
  3. Leyland KM, Gates LS, Sanchez-Santos MT, et al.; PCCOA Steering Committee. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res. 2021;33(3):529-45. doi: 10.1007/s40520-020-01762-2
  4. Sharma PK, Reddy BM, Ganguly E. Frailty Syndrome among oldest old Individuals, aged ≥80 years: Prevalence & Correlates. J Frailty Sarcopenia Falls. 2020;5(4):92-101. doi: 10.22540/JFSF-05-092
  5. Thinuan P, Siviroj P, Lerttrakarnnon P, Lorga T. Prevalence and Potential Predictors of Frailty among Community-Dwelling Older Persons in Northern Thailand: A Cross-Sectional Study. Int J Environ Res Public Health. 2020;17(11):4077. doi: 10.3390/ijerph17114077
  6. Yoshimura N, Nakamura K, Tanaka S. Epidemiology of the Locomotive Organ Diseases. Health Issues and Care System for the Elderly. 2019:69-81. doi: 10.1007/978-981-13-1762-0_5
  7. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и др. Клинические рекомендации «Старческая астения». Российский журнал гериатрической медицины. 2020;1:11-46 [Tkacheva ON, Kotovskaya YuV, Runikhina NK, et al. Clinical guidelines on frailty. Russian Journal of Geriatric Medicine. 2020;1:11-46 (in Russian)]. doi: 10.37586/2686-8636-1-2020-11-46
  8. Arora M, Sun CL, Ness KK, et al. Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study. JAMA Oncol. 2016;2(10):1277-86. doi: 10.1001/jamaoncol.2016.0855
  9. Cacciatore F, Della-Morte D, Basile C, et al. Long-term mortality in frail elderly subjects with osteoarthritis. Rheumatology (Oxford). 2014;53(2):293-9. doi: 10.1093/rheumatology/ket348
  10. Meessen JMTA, Leichtenberg CS, Tilbury C, et al. Frailty in end-stage hip or knee osteoarthritis: validation of the Groningen Frailty Indicator (GFI) questionnaire. Rheumatol Int. 2018;38(5):917-24. doi: 10.1007/s00296-017-3868-1
  11. Salaffi F, Farah S, Di Carlo M. Frailty syndrome in rheumatoid arthritis and symptomatic osteoarthritis: an emerging concept in rheumatology. Acta Biomed. 2020;91(2):274-96. doi: 10.23750/abm.v91i2.9094
  12. Knox PJ, Coyle PC, Pugliese JM, et al. Hip osteoarthritis signs and symptoms are associated with increased fall risk among community-dwelling older adults with chronic low back pain: a prospective study. Arthritis Res Ther. 2021;23(1):71. doi: 10.1186/s13075-021-02455-5
  13. De Ceuninck F, Fradin A, Pastoureau P. Bearing arms against osteoarthritis and sarcopenia: when cartilage and skeletal muscle find common interest in talking together. Drug Discov Today. 2014;19(3):305-11. doi: 10.1016/j.drudis.2013.08.004
  14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8
  15. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и др. Клинические рекомендации «Старческая астения». Часть 2. Российский журнал гериатрической медицины. 2020;2:115-30 [Tkacheva ON, Kotovskaya YuV, Runikhina NK, et al. Clinical guidelines frailty. Part 2. Russian Journal of Geriatric Medicine. 2020;2:115-30 (in Russian)]. doi: 10.37586/2686-8636-2-2020-115-130
  16. Воробьева Н.М., Ткачева О.Н., Котовская Ю.В., и др. Российское эпидемиологическое исследование ЭВКАЛИПТ: протокол и базовые характеристики участников. Российский журнал гериатрической медицины. 2021;1:35-43 [Vorobyeva NM, Tkacheva ON, Kotovskaya YuV, et al. Russian epidemiological study EVKALIPT: protocol and basic characteristics of participants. Russian Journal of Geriatric Medicine. 2021;1:35-43 (in Russian)]. doi: 10.37586/2686-8636-1-2021-35-43
  17. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185-99. doi: 10.1093/bmb/lds038
  18. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207-13. doi: 10.1002/art.24021
  19. Castell MV, van der Pas S, Otero A, et al. Osteoarthritis and frailty in elderly individuals across six European countries: results from the European Project on OSteoArthritis (EPOSA). BMC Musculoskelet Disord. 2015;16:359. doi: 10.1186/s12891-015-0807-8
  20. Prieto-Alhambra D, Judge A, Javaid MK, et al. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014;73(9):1659-64. doi: 10.1136/annrheumdis-2013-203355
  21. Jeon H, Lee SU, Lim JY, et al. Low skeletal muscle mass and radiographic osteoarthritis in knee, hip, and lumbar spine: a cross-sectional study. Aging Clin Exp Res. 2019;31(11):1557-62. doi: 10.1007/s40520-018-1108-5
  22. Misra D, Fielding RA, Felson DT, et al.; MOST study. Risk of Knee Osteoarthritis With Obesity, Sarcopenic Obesity, and Sarcopenia. Arthritis Rheumatol. 2019;71(2):232-7. doi: 10.1002/art.40692
  23. Doré AL, Golightly YM, Mercer VS, et al. Lower-extremity osteoarthritis and the risk of falls in a community-based longitudinal study of adults with and without osteoarthritis. Arthritis Care Res (Hoboken). 2015;67(5):633-9. doi: 10.1002/acr.22499
  24. Hampton SN, Nakonezny PA, Richard HM, Wells JE. Pain catastrophizing, anxiety, and depression in hip pathology. Bone Joint J. 2019;101-B(7):800-7. doi: 10.1302/0301-620X.101B7.BJJ-2018-1309.R1
  25. Rathbun AM, Shardell MD, Ryan AS, et al. Association between disease progression and depression onset in persons with radiographic knee osteoarthritis. Rheumatology (Oxford). 2020;59(11):3390-9. doi: 10.1093/rheumatology/keaa141
  26. Tanaka R, Ozawa J, Kito N, Moriyama H. Efficacy of strengthening or aerobic exercise on pain relief in people with knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Clin Rehabil. 2013;27(12):1059-71. doi: 10.1177/0269215513488898
  27. Dean E, Hansen RG. Prescribing optimal nutrition and physical activity as “first-line” interventions for best practice management of chronic low-grade inflammation associated with osteoarthritis: evidence synthesis. Arthritis. 2012;2012:560634. doi: 10.1155/2012/560634
  28. Grässel S, Muschter D. Recent advances in the treatment of osteoarthritis. F1000Res. 2020;9:F1000 Faculty Rev-325. doi: 10.12688/f1000research.22115.1
  29. Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008
  30. Largo R, Alvarez-Soria MA, Díez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003;11(4):290-8. doi: 10.1016/s1063-4584(03)00028-1
  31. Jang BC, Sung SH, Park JG, et al. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem. 2007;282(38):27622-32. doi: 10.1074/jbc.M610778200
  32. Beaudart C, Lengelé L, Leclercq V, et al. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020;80(18):1947-59. doi: 10.1007/s40265-020-01423-8
  33. Yang W, Sun C, He SQ, et al. The Efficacy and Safety of Disease-Modifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis – a Systematic Review and Network Meta-Analysis. J Gen Intern Med. 2021;36(7):2085-93. doi: 10.1007/s11606-021-06755-z
  34. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555-67. doi: 10.1002/art.22371
  35. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-6. doi: 10.1016/S0140-6736(00)03610-2
  36. Pavelká K, Gatterová J, Olejarová M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113-23. doi: 10.1001/archinte.162.18.2113
  37. Biver E, Berenbaum F, Valdes AM, et al. Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Res Rev. 2019;55:100946. doi: 10.1016/j.arr.2019.100946
  38. Громова О.А., Торшин И.Ю., Наумов А.В., Максимов В.А. Хемомикробиомный анализ глюкозамина сульфата, пребиотиков и нестероидных противовоспалительных препаратов. Фармакоэкономика. Современная Фармакоэкономика и Фармакоэпидемиология. 2020;13(3):270-81 [Gromova OA, Torshin IYu, Naumov AV, Maksimov VA. Chemomicrobiomic analysis of glucosamine sulfate, prebiotics and non-steroidal antiinflammatory drugs. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya/Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(3):270-81 (in Russian)]. doi: 10.17749/2070-4909/farmakoekonomika.2020.049
  39. Navarro SL, Levy L, Curtis KR, et al. Modulation of Gut Microbiota by Glucosamine and Chondroitin in a Randomized, Double-Blind Pilot Trial in Humans. Microorganisms. 2019;7(12):610. doi: 10.3390/microorganisms7120610
  40. Васильева Л.В., Евстратова Е.Ф., Никитин А.В. Эффективность лечения глюкозамин сульфатом (Сустагард артро) больных остеоартритом в поликлинических условиях. Фарматека. 2016;13(326)39-43 [Vasilieva LV, Evstratova EF, Nikitin AV. Efficacy of treatment with glucosamine sulfate (Sustaguard artro) in patients with osteoarthritis in the outpatient settings. Farmateka. 2016;13(326)39-43 (in Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The prevalence of osteoarthritis in individuals ≥65 years old, depending on age (n=4295).

Download (62KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies